New hope for pancreatic cancer: drug combo trial launches
NCT ID NCT07342725
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called IBI363 combined with chemotherapy for people with advanced pancreatic cancer that has worsened after first treatment. About 48 patients will receive the combination to see if it is safe and helps control the cancer. The goal is to slow disease progression and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI363 combined with chemotherapy
What this could lead to
If successful, this could offer a new second-line treatment option for advanced pancreatic cancer patients who have failed initial therapy.
What could go wrong
This is an early-phase trial with only 48 participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.